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Introduction: The primary objective of the present systematic review
was to evaluate the safety and efficacy of extrapleural pneumonectomy
(EPP) for patients with malignant pleural mesothelioma.
Methods: A systematic review of relevant studies identified through
five online search databases was performed. Two reviewers inde-
pendently appraised each study.
Results: Thirty-four of 58 relevant studies from 26 institutions
containing the most updated data were evaluated for survival and
perioperative outcomes after EPP. The median overall survival
varied from 9.4 to 27.5 months, and 1-, 2-, and 5-year survival rates
ranged from 36 to 83%, 5 to 59%, and 0 to 24%, respectively.
Overall perioperative mortality rates ranged from 0 to 11.8%, and
the perioperative morbidity rates ranged from 22 to 82%. Quality of
life assessments from three studies reported improvements in nearly
all domains at 3 months postoperatively. Patients who underwent
trimodality therapy involving EPP and adjuvant chemoradiotherapy
had a median overall survival of 13 to 23.9 months.
Discussions: The current evidence suggests that selected patients
with malignant pleural mesothelioma may benefit from EPP, espe-
cially when combined with neoadjuvant or adjuvant chemotherapy
and adjuvant radiotherapy.
Key Words: Malignant pleural mesothelioma, Extrapleural pneu-
monectomy, Systematic review.
(J Thorac Oncol. 2010;5: 1692–1703)
Malignant pleural mesothelioma (MPM) is a rare andaggressive disease arising from the pleural mesothe-
lium, with a reported survival of less than 12 months.1
Despite advances in modern systemic chemotherapy, long-
term survival in patients with MPM remains limited.2 Be-
cause of the lag time between asbestos exposure and disease
manifestation, the peak incidence of MPM in the United
States is projected to be between 2010 and 2020. Other
developed countries show similar epidemiological trends, and
the health, medicolegal, and industrial implications of this
disease will continue to intensify in the years to come.3–5
The standard of care for patients with MPM has not
been established. Extrapleural pneumonectomy (EPP) has
been performed as a treatment option.6–63 This procedure
involves en bloc resection of the parietal pleurae, lung,
ipsilateral hemidiaphragm, and ipsilateral pericardium. A
number of studies have demonstrated encouraging results for
selected patients with MPM who underwent EPP. However,
because of the relentless nature of the disease, treatment
failure after EPP alone remains high.48 Since then, a number
of institutions have combined EPP with adjuvant chemother-
apy and/or radiotherapy. In comparison with procedures such
as pleurectomy and decortication, EPP aims to achieve rad-
ical cytoreduction and facilitate maximal delivery of postop-
erative radiotherapy.
Despite a heightened interest in EPP over the past
decade, concerns about the morbidity and mortality of this
surgical procedure, and its efficacy, have delayed a consensus
in its practice. In addition, there is a lack of robust clinical
data on prognostic factors for overall survival and quality of
life evaluation. To date, no randomized controlled trials
(RCTs) have been conducted to examine the potential bene-
fits of EPP. The most recent systematic review conducted by
Maziak et al.64 provided an informative summary of existing
literature up to February 2004. However, significant changes
have taken place since that time. More recently, innovative
multimodalities such as neoadjuvant chemotherapy and hy-
perthermic intraoperative chemotherapy (HIOC) have been
evaluated.6–8 The current systematic review aims to deter-
mine the efficacy of EPP either alone or as part of a multi-
modality therapy in the current medical setting, with a pri-
mary focus on survival and perioperative outcomes. In
addition, quality of life assessments were also systematically
examined.
METHODS
Literature Search Strategy
Electronic searches were performed using Ovid Med-
line, EMBASE, Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, and Da-
tabase of Abstracts of Review of Effectiveness from January
1985 to January 2010. To achieve the maximum sensitivity of
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the search strategy and identify all studies, we combined
“mesothelioma” as a Medical Subject Headings (MeSH) term
or a keyword and “pneumonectomy” as a MeSH term or
keyword. The reference lists of all retrieved articles were
reviewed for further identification of potentially relevant
studies. All relevant articles identified were assessed with
application of inclusion and exclusion criteria.
Selection Criteria
Eligible studies for the present systematic review in-
cluded those in which patients with histologically proven
MPM were treated by EPP. Adjuvant therapy included che-
motherapy, radiotherapy, photodynamic therapy, and hyper-
thermic or normothermic intrapleural chemotherapy. Neoad-
juvant therapy included systemic chemotherapy. For studies
that included patients who underwent EPP as a subset of
patients who had other treatments, results for patients who
underwent EPP were extracted when possible. When centers
have published duplicate trials with accumulating numbers of
patients or increased lengths of follow-up, only the most
complete reports were included for qualitative appraisal. It is
acknowledged that criteria for patient selection for EPP
varied among institutions and sometimes within an institution
in different time periods. All publications were limited to
human subjects and in English language.
Abstracts, case reports, conference presentations, edi-
torials, and expert opinions were excluded. Review articles
are omitted due to potential publication bias and possible
duplication of results. Studies published before 1990 and
those that included 10 or fewer patients who underwent EPP
were also excluded.
Data Extraction and Critical Appraisal
Findings from initial scoping searches were used to
decide outcomes for the present review. The primary out-
comes included overall survival, 30-day mortality and mor-
bidity, and quality of life assessments. The secondary out-
comes included disease-free survival, recurrence rates,
prognostic factors on overall survival, intraoperative blood
loss, length of hospitalization, and operation time. All data
were extracted from article texts, tables, and figures. Two
investigators (C.Q.C. and T.D.Y.) independently reviewed
each retrieved article. Discrepancies between the two review-
ers were resolved by discussion and consensus. The final
results were reviewed by the senior investigators (P.G.B. and
B.C.M.).
RESULTS
Quantity of Trials
A total of 428 references were identified through the
five electronic database searches. After exclusion of duplicate
or irrelevant references, 121 potentially relevant articles were
retrieved for more detailed evaluation. After applying the
selection criteria, 58 remained for assessment (Table 1). A
number of centers published studies with duplicating patients
at different follow-up periods or different primary objectives.
Thirty-four of 58 studies from 26 institutions containing the
most complete or updated data were included in the final
analysis on survival and perioperative outcomes (Table 2).
Overall, a total of 3749 patients who underwent EPP for
MPM were identified from the 58 selected studies, with 2462
patients included in the final evaluation.
Assessment of Survival
A summary of survival outcomes for patients undergo-
ing EPP for MPM is presented in Table 2. The median overall
survival ranged from 9.4 to 27.5 months.6–63 However, it
should be noted that a number of studies calculated survival
from the date of diagnosis or commencement of chemother-
apy rather than the date of surgery.17,35,43,48–50,56 The 1-, 2-,
3-, and 5-year survival rates varied from 36 to 83%, 5 to 59%,
0 to 41%, and 0 to 24%, respectively. Median disease-free
survival ranged from 7 to 19 months, and an additional study
reported 20 months for distant recurrence and 26 months for
local recurrence.6–63 When the middle two quartiles of the
included studies are analyzed, median overall survival ranged
from 12 to 20 months, and the 1-, 2-, 3-, and 5-year survival
rates varied from 50 to 68%, 26.5 to 40.5%, 19 to 30%, and
10 to 19%, respectively.6–63
Assessment of Perioperative Outcomes
The perioperative outcomes are presented in Table 2.
The overall perioperative mortality rates ranged from 0 to
11.8%, with the middle two quartiles falling between 3.7%
and 7.6%. Overall perioperative morbidity rates ranged from
22 to 82%, and major morbidity rates ranged from 12.5 to
48%.6–63 A number of studies reported the number of events
rather than the number of patients with postoperative com-
plications and were excluded from the analysis as it was not
possible to determine how many patients had multiple com-
plications.14,15,19,49,52 Intraoperative blood loss ranged from
500 to 2314 ml. Operative time ranged from 3.25 to 6.5
hours. Hospitalization duration ranged from 8 to 43 days.6–63
Assessment of Quality of Life
Three studies reported quality of life assessments using
a variety of questionnaires. Ribi et al.53 and Weder et al.35
assessed 45 patients who underwent EPP and evaluated their
quality of life using the Rotterdam Symptom Checklist
(RSCL) and Schedule for the Evaluation of Quality of Life-
Direct Weighting (SEIQoL-DW) before surgery, on day 1 of
cycle 3, and at 1 month, 3 months, and 6 months postopera-
tively. Results indicated that both RSCL and SEIQoL-DW
scores remained stable during chemotherapy, followed by a
significant deterioration 1 month postoperatively. RSCL
overall scores improved at 3 months but remained beneath
baseline levels until 6 months after surgery. SEIQoL scores
improved to baseline levels at 3 months but deteriorated at 6
months. Ambrogi et al.39 used the Short-Form-36 (SF-36)
item and St. George’s Respiratory Questionnaire to assess 16
patients who underwent EPP preoperatively and at 3, 6, 12,
and 24 months postoperatively. Comparable with the Swiss
reports, this study found improvements in nearly all the
SF-36 domains at 3 months. After 12 months, only physical
domains remained significantly above the baseline levels,
followed by deterioration in all domains at 24 months. Sim-
ilarly, the St. George’s Respiratory Questionnaire results
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found improvements in all domains at 3 months, remaining
stable at 12 months, followed by deterioration at 24 months.
Interestingly, SF-36 physical-component-summary at 3
months postoperatively was found to be correlated signifi-
cantly with overall survival.
EPP With Adjuvant Chemo/Radiotherapy
A large number of studies on EPP in recent years have
included subsets of patients who received adjuvant or neoad-
juvant chemotherapy with radiotherapy. However, only 14
studies focused on trimodality therapy (TMT) and provided
detailed treatment protocols. A summary of chemotherapy
regimens, perioperative outcomes, and survival data of these
studies are presented in Table 3. One of the earlier studies
involving the largest number of patients to date reported a
retrospective series of 183 patients who completed EPP,
adjuvant chemotherapy, and adjuvant radiotherapy.18 The
chemotherapy regimen changed during the study period, with
earlier patients receiving doxorubicin and cyclophosphamide
with or without cisplatin, followed by later patients who
received carboplatin and paclitaxel. A number of other stud-
ies that included adjuvant chemotherapy also varied in their
regimens (Table 3). Generally, agents such as carboplatin,
cyclophosphamide, and gemcitabine have largely been re-
placed by pemetrexed and cisplatin. Perioperative mortality
for TMT involving adjuvant chemoradiotherapy ranged from
0 to 11%, and the median overall survival ranged from 13 to
23.9 months.18,19,39,43,55,57,60
Neoadjuvant Chemotherapy, EPP, and
Adjuvant Radiotherapy
More recently, TMT involving neoadjuvant therapy has
been reported in several centers. The rationale for this regi-
men originated from encouraging results for patients with
stage IIIA non-small cell lung cancer and aiming to increase
the proportion of patients who are able to complete TMT after
EPP.6 Common neoadjuvant regimens included gemcitabine
and cisplatin, with more recent studies using pemetrexed and
cisplatin.6,32,50 The proportion of intention-to-treat (ITT) pa-
tients who completed the planned TMT regimens ranged
from 50 to 71% and the proportion of ITT patients who
completed neoadjuvant chemotherapy and EPP ranged from
74 to 84%. Perioperative mortality rates ranged from 0 to
6.7%.6,32,35–37,50,56 Median overall survival for the ITT pop-
ulation ranged from 14 to 25.5 months, although some sur-
vival data were calculated from the date of diagnosis or
chemotherapy rather than the date of surgery.32,35,36,50
Other Therapies
A number of novel therapeutic approaches have been
described in several studies. To achieve maximum tumor
cytoreduction after EPP, HIOC was reported by Sugarbaker
and coworkers14,15 in two studies. The goal of HIOC was to
reduce local recurrence by achieving enhanced local drug
delivery at the site of resection in the thorax. A phase I study
involving 29 patients who underwent EPP and HIOC with an
escalating dose of cisplatin reported a 30-day mortality rate of
3.4% and a median overall survival of 20 months.14 The
following phase II study analyzed 92 patients who completedTA
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EPP and HIOC at a higher dosage and reported a 30-day
mortality rate of 1% and an overall median survival of 13.1
months.15 Morbidity had been relatively high in both studies,
with 61 and 84 major adverse events, respectively. van
Sandick et al.45 conducted a comparative study involving 20
patients who either underwent EPP (n  8) or P/D (n  12)
followed by HIOC and compared their outcome with 15
patients who underwent EPP and adjuvant radiotherapy. The
median overall survival was 11 months and 29 months,
respectively. The authors also found that patients in the HIOC
group had a longer operative time, a longer intensive care unit
stay, and a shorter time to local tumor recurrence than
patients who underwent EPP and adjuvant radiotherapy.
Normothermic intrapleural chemotherapy was reported
in one study by Aziz et al.,59 who compared 51 patients who
completed EPP, adjuvant intrapleural carboplatin, and sys-
temic chemotherapy with 13 patients who underwent EPP
alone. This study found the median overall survival to be
significantly improved in the group that received adjuvant
intrapleural and systemic chemotherapy (35 versus 13
months), but it was unclear which form of adjuvant chemo-
therapy was responsible for the improvement.
One study reported the use of intraoperative photody-
namic therapy. Schouwink et al.46 prescribed 0.075 to 0.15
mg/kg of meta-tetrahydroxyphenylchlorin to 28 patients, with
26 patients undergoing illumination 4 to 6 days later. Al-
though local disease control was achieved in 50% of the
patients, the authors reported a 30-day mortality of 10.7% and
a median survival of 10 months. Overall postoperative mor-
bidity was reported as 82%.
DISCUSSION
MPM is most commonly caused by exposure to asbes-
tos, which provokes carcinogenesis through its physical com-
position.65 Traditionally, MPM has been regarded by the
medical community as a preterminal condition with an ex-
pected life expectancy of less than 12 months. This nihilistic
view is due to the aggressive nature of the disease and its
resistance to any single-modality treatment.1,65 Early chemo-
therapy regimens included anthracyclines such as doxorubi-
cin and platinum compounds such as cisplatin, with response
rates of usually less than 20% and a median survival of less
than 12 months.66–68 More recently, the combination of
pemetrexed and cisplatin has emerged as the first-line che-
motherapy regimen, with a multicenter, randomized, single-
blinded study assigning 226 patients to this treatment, result-
ing in a significantly longer median survival than cisplatin
alone (12.1 versus 9.3 months, p  0.020).2 EPP was first
described by Sarot69 for the treatment of tuberculous empy-
ema in 1949. Butchart et al.70 were one of the first to perform
EPP for patients with MPM, with a study in 1976 reporting a
prohibitive perioperative mortality rate of 31% and a median
survival of only 10 months. In a personal communication
reported by Treasure et al.71 Butchart was quoted as saying
“We have recently analyzed our experience with both pleu-
ropneumonectomy and pleurectomy/decortication for me-
sothelioma. The very strong message from this analysis is
that adjuvant therapy is essential to achieve any degree of
long term survival with either surgical procedure.”
Since those early reports, advances in patient selection,
surgical technique, and perioperative care have enabled im-
provements in the surgical outcomes of patients with MPMwho
undergo EPP. In addition, studies involving adjuvant and neo-
adjuvant therapies such as systemic chemotherapy, intrapleural
chemotherapy, radiotherapy, and photodynamic therapy have
reported varying degrees of success. Overall, the current sys-
tematic review on EPP for patients with MPM found a periop-
erative mortality rate of 0 to 11.8% and a median overall
survival of 9.4 to 27.5 months. The majority of patients were
within the middle two quartiles of these ranges, and the periop-
erative mortality rate in these studies ranged from 3.7 to 7.6%,
with an overall median survival of 12 to 20 months. The
reporting of postoperative complications varied between institu-
tions, and the reported overall morbidity rate was between 22%
and 82%, with major morbidities between 12.5% and 48%.
According to the largest series to date involving 385 patients
who underwent EPP, the most common morbidities include
atrial arrhythmia, respiratory failure, respiratory infections, pul-
monary embolus, and myocardial infarction.7 Quality of life
assessments were found in three studies, two of which reported
on the same set of patients who underwent TMT. All three
studies found improvements in nearly all domains at 3 months
postoperatively, either close to or better than at baseline levels
preoperatively.35,39,53
An important subset of patients identified in the current
systematic review includes those who received TMT, which
is becoming the preferred treatment in a number of institu-
tions. One of the earlier studies on TMT consisted of 183
patients who completed EPP, adjuvant chemotherapy, and
adjuvant radiotherapy.18 Selection criteria in this large series
included good performance status, adequate organ function,
and resectable tumor without evidence of metastatic disease
on imaging. The results of this retrospective study was
encouraging, with a perioperative mortality rate of 3.8%, and
a median overall survival of 19 months for patients who
survived the first 30 days. The authors also found that patients
with epithelial cell type, negative extrapleural nodes, and
complete resection margins had a significantly improved
survival outcome on multivariate analysis. Following this
study, two prospective series have shown similar outcomes,
with perioperative mortality of 5% and median overall sur-
vival of more than 20 months for patients who completed
TMT.55,57
More recently, the use of neoadjuvant chemotherapy has
been reported in seven studies, with the aim of maximizing
cytoreduction and increasing the proportion of patients who are
able to complete the TMT regimen after EPP. The largest
prospective study to date by Krug et al.6 incorporated three
cycles of neoadjuvant cisplatin and pemetrexed followed by
EPP and adjuvant radiotherapy in the form of 54 Gy to the
hemithorax in 1.8 Gy fractions. Inclusion criteria were T1-3
N0-2 disease, no prior surgical resection, adequate organ func-
tion, and performance status 0 to 1. Of the 77 patients included
in the ITT population, 52% completed the planned TMT regi-
men. Perioperative mortality was 3.7%, and the median overall
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survival rates for the ITT population and patients who completed
TMT were 16.8 months and 29.1 months, respectively. Other
trials on TMT involving neoadjuvant chemotherapy included in
the current systematic review have also shown encouraging
results, with the perioperative mortality rate of 0 to 6.7% and
median overall survival of 14 to 25.5 months for the ITT
population.6,32,35–37,50,56 Disease-free survival for patients who
had completed neoadjuvant chemotherapy and EPP ranged from
13.5 to 18.3 months.6,32,35–37,50,56 Despite these findings, it
should be noted that patients who received neoadjuvant chemo-
therapy and had evidence of disease progression were often
excluded from undergoing EPP. From a sceptical perspective,
the improvement in overall survival could reflect a selection of
patients with less aggressive disease rather than treatment effi-
cacy. A method to assess the proportion of patients who com-
plete TMT is to calculate the completion rate from the ITT
population. For studies on TMT involving neoadjuvant chemo-
therapy, this ranged from 50 to 71%.6,32,35–37,50,56
It has to be acknowledged that there was a distinct
heterogeneity among the assessed studies, including patient
selection, treatment regimens, follow-up methods, and even
survival calculation. Patient selection using performance sta-
tus and staging of disease at the time of operation differed
between institutions and at times between different study
periods within one institution. Rusch and Venkatraman11
highlighted the importance of staging in the treatment of
MPM and advocated for the systematic use of a unified
staging system. However, individual institutions still vary in
the staging system they use. Generally, patients eligible for
EPP included those who have tumors which appeared resect-
able on preoperative investigations, good performance status,
and adequate cardiorespiratory, hepatic, and renal function.
Presence of N2 lymph node involvement was found to be a
significant prognostic factor on multivariate analysis when
grouped with internal thoracic lymph nodes and compared
with N1 and N0 disease (hazard ratio: 1.7, p  0.0001).8
However, the practice of routine mediastinoscopy and exclu-
sion of patients with mediastinoscopy-positive N2 disease
from undergoing EPP remains controversial.25 Median fol-
low-up of all the studies in the current systematic review
ranged from 8.8 to 31.2 months but varied greatly in the form
and frequency of radiologic follow-up.6–63 Partly because of
this, recurrence rates and disease-free survival should be
interpreted with caution. Finally, overall survival was re-
ported from the date of chemotherapy or diagnosis from a
number of studies, and this will inevitably present a longer
survival compared with studies that calculate survival from
the date of surgery.17,35,43,48–50,56 Future studies should aim to
be conducted in a prospective manner with careful patient
selection and regular radiographic follow-up, with clear and
uniform reporting of perioperative and long-term survival
outcomes.
Because of the relative rarity of MPM and its aggres-
sive nature, as well as a multitude of challenges in the
randomization process, there has been no completed RCT to
date. Authors of the upcoming Mesothelioma and Radical
Surgery trial pointedly highlighted numerous potential flaws
in the evidence from the current literature based primarily on
case series studies.71–73 At the time of writing, this group
reported that 50 of 112 potentially eligible patients have been
randomized in their planned trial, with 24 assigned to un-
dergo EPP and 26 to have continued best care.74 If this trial
is successfully completed, the results may provide additional
insight on any potential benefit of EPP as part of a multimo-
dality treatment. However, it remains to be seen if data from
one RCT will be able to establish a firm consensus within the
surgical community, especially considering the differences in
patient selection, surgical experience, and treatment protocols
between centers. Alternatively, a multiinstitutional registry
based on an ITT principle may provide valuable information
on prognostically similar patients who undergo different
management pathways.
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